WARRINGTON, Pa., Nov. 21, 2012 /PRNewswire/ -- Discovery
Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology
company dedicated to advancing a new standard in respiratory
critical care, today announced that management will present an
overview and update on the Company's business at the
25th Annual Piper Jaffray Health Care Conference on
Tuesday, December 3, 2013 at
1:10 PM ET. The conference will
be held at the New York Palace Hotel in New York, New York.
Discovery Laboratories, Inc. is a specialty biotechnology
company focused on advancing a new standard in respiratory critical
care. Discovery Labs' technology platform includes its novel
proprietary KL4 surfactant, a synthetic, peptide-containing
surfactant that is structurally similar to pulmonary surfactant,
and its proprietary drug delivery technologies being developed to
enable efficient delivery of aerosolized KL4 surfactant and other
inhaled therapies. Discovery Labs' strategy is initially
focused on neonatology and improving the management of respiratory
distress syndrome (RDS) in premature infants. Discovery Labs
believes that its RDS product portfolio has the potential to become
the new standard of care for RDS and, over time, enable the
treatment of a significantly greater number of premature infants
who could benefit from surfactant therapy but are currently not
treated.
For more information, please visit the Company's website at
www.Discoverylabs.com.
Forward-Looking Statements
To the extent
that statements in this press release are not strictly historical,
all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
certain risks and uncertainties that could cause actual results to
differ materially from the statements made. Examples of such risks
and uncertainties are described in Discovery Labs' filings with the
Securities and Exchange Commission including the most recent
reports on Forms 10-K, 10-Q and 8-K, and any amendments
thereto.
SOURCE Discovery Laboratories, Inc.